As the seasons change, bringing warm days and the promise of outdoor adventures, millions of Europeans brace themselves for the onset of allergy symptoms1. For many, these symptoms are more than just a minor inconvenience; they significantly impact daily life. Yet, without an accurate diagnosis, countless individuals continue to suffer unnecessarily.
At Thermo Fisher Scientific, we’re working to make the world healthier, cleaner, and safer. Our cutting-edge in-vitro diagnostics empower those suffering from allergies to receive precise diagnoses, ensuring they get the right test at the right time.
The economic burden of allergies is staggering, with costs ranging from €55 to €151 billion annually across Europe2. These costs encompass absenteeism, healthcare, and other related expenses. Symptoms can vary from mild annoyances, like a runny nose, to life-threatening anaphylaxis, forcing individuals to live in constant fear of their next reaction.
Accurate diagnosis is transformative. Over 50 years ago, researchers from Uppsala University discovered the immunoglobulin E (IgE) antibody, revolutionizing our understanding of allergic reactions. This breakthrough led to the development of specific IgE diagnostic tests, benefiting millions worldwide.
Our allergen sensitization tests can detect specific IgE antibodies to over 550 different allergens, helping clinicians pinpoint their patients’ specific triggers3
. These tests also help clinicians to evaluate the severity of allergies, informing personalized treatment plans. Fast, automated, and easy to perform, our tests provide precise results to identify sensitization to allergic triggers4, enabling better-informed decisions on treatment and management.
We cultivate hundreds of potential allergens on our farm in southern Sweden, harvesting pollen, dust mites, and other sensitizing substances. This unique approach contributes to our reputation as the gold standard in in-vitro allergy diagnostics.
Diagnosis is just the beginning. It is the key to managing, treating, and even preventing allergies. It empowers patients and clinicians to make informed decisions sooner, breaking the cycle of uncertainty.
Our immunodiagnostics business has consistently pushed the boundaries of innovation and excellence. Our commitment to advancing allergy diagnostics has not only driven our success but has also made a tangible difference in the lives of countless individuals. Our strategic vision and unwavering dedication inspire our teams to strive for excellence every day.
Let’s continue to lead the charge in allergy diagnostics, making a tangible difference in the lives of those affected.
Join us in our mission to transform lives. Connect with us on LinkedIn and be part of the journey towards a healthier, allergy-free future.
Santhosh Nair
Santhosh Nair is President, ImmunoDiagnostics Division at Thermo Fisher Scientific, guiding teams that create advanced tests for allergy and autoimmune conditions. With more than twenty years of global leadership experience across life sciences, diagnostics, medical devices and software, he has driven major product launches and complex business transformations. He is committed to developing high-performing teams and building impactful, mission-focused innovations.
1. Allergy UK. Statistics and figures. Available at: https://www.allergyuk.org/about-allergy/statistics-and-figures/. Last accessed: September 2025.↩︎
2. Zuberbier T, Lotvall J, Simoens S, Subramanian SV, Church MK. Economic burden of inadequate management of allergic diseases in the € European Union: a GA2 LEN review. Allergy 2014; 69: 1275–1279.↩︎
3. Thermo Fisher Scientific. Whole allergen. ImmunoCAP™ Specific IgE single allergens. Available at: https://www.thermofisher.com/phadia/gb/en/our-solutions/immunocap-allergy-solutions/specific-ige-single-allergens/whole-allergen.html. Last accessed: September 2025.↩︎
4. Casas, M., Esteban, Á., González-Muñoz, M., Labrador-Horrillo, M., Pascal, M. and Teniente-Serra, A. (2020) VALIDA project: Validation of allergy in vitro diagnostics assays (Tools and recommendations for the assessment of in vitro tests in the diagnosis of allergy). Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, Vol. 1 (Issue 4), pp. 20200051. https://doi.org/10.1515/almed-2020-0051 .↩︎
